Application · Mass Spectrometry Imaging

Drug Metabolism Analysis: Tracking 'Drug' and 'Metabolite' In-Situ

After entering the body, a drug is converted into a series of metabolites, which may be more active or more toxic. Drug metabolism analysis uses mass spectrometry imaging (MSI) to acquire point by point on sections, presenting in-situ the spatial distribution of parent drug and its metabolites in different tissues and at different time points, moving metabolism research from 'homogenate concentration' to 'spatial trajectory'.
Table of Contents
1. The Role of MSI in Drug Metabolism2. Time Dimension and Multi-Organ Comparison3. Connection with Toxicology and Safety Evaluation4. Quantitative Boundaries and Engineering Deployment
Schematic principle: ion source ionizes the sample spot-by-spot Tissue section Sample Ionization beam Drug Metabolism Analysis: Tracking 'Drug' and 'Metabolite' In-Situ Ions MS analyzer
Drug Metabolism Analysis: Tracking 'Drug' and 'Metabolite' In-Situ — schematic diagram

1. The Role of MSI in Drug Metabolism

The application notes of the Neo-Source MSI DPI list pharmacokinetics as a key area: used for new drug R&D, distribution studies of drugs and metabolites in different organs at different times, drug quantification, drug discovery and distribution research, and herbal mixtures. DPI is matrix-free, exhibits low ion suppression, and can directly analyze complex biological samples, making it compatible with Agilent, AB SCIEX and Thermo instruments.

Its resolution is adjustable in the 20–200 μm range, covering various spatial analysis needs from organ scale to local lesions; for scenarios requiring single-cell/subcellular scale, MSI LDPI provides 2–3 μm matrix-free ambient imaging as a supplement.

2. Time Dimension and Multi-Organ Comparison

Drug metabolism is dynamic. Sampling and imaging at different time points after administration can reconstruct the 'entry–enrichment–clearance' curve of compounds in the body; sections from multiple time points and multiple organs (liver, kidney, brain, intestine, tumor, etc.) placed side by side depict a complete spatiotemporal distribution.

In the DPI case, tests on animal tissues and plant leaves showed that, in both positive and negative ion modes compared with traditional DESI, more than a hundred additional secondary metabolites could be detected, with overall signal enhanced by 1–3 orders of magnitude; this sensitivity advantage also benefits multi-time-point spatial tracking of low-abundance drugs and metabolites.

3. Connection with Toxicology and Safety Evaluation

Abnormal metabolite enrichment often precedes visible pathological changes. If MSI finds abnormal distribution of drugs/metabolites in metabolically active or non-target organs, it can serve as an early hint of potential toxicity, guiding dose optimization and formulation improvement. Registering the distribution map with adjacent H&E sections can also precisely overlay molecular signals onto damaged tissue structures.

The engineering value of matrix-free preparation is highlighted here: the two Neo-Source imaging sources are matrix-free and measure on demand, reducing sample handling from 'half a day at best' to 'measure on demand', significantly accelerating metabolism-evaluation experiments requiring many time points and dose groups.

4. Quantitative Boundaries and Engineering Deployment

MSI gives relative spatial distribution and ion-intensity images; quantification requires standard curves or internal-standard methods, considering histology and dosing regimen. It excels at localization and discovery; the gold standard for absolute quantification is still often complemented by LC-MS.

Engineered, the two Neo-Source imaging sources are compatible with mainstream mass spectrometers and provide a self-developed titanium-alloy ion transfer tube that does not damage the sample at the front end and is detachable for cleaning, enabling drug metabolism analysis to move stably and reproducibly from research projects into quality-control and screening production lines.

Frequently Asked Questions (FAQ)

Where is the difference between drug metabolism analysis and ordinary metabolomics?
Ordinary metabolomics homogenizes to measure average concentration, losing spatial information; MSI presents the spatial distribution of drugs and metabolites in-situ on sections, preserving tissue structure.
Can MSI achieve absolute quantification of drug metabolism?
It mainly provides relative spatial distribution and ion-intensity images; absolute quantification usually requires standard curves, internal standards or LC-MS validation; MSI is strong in localization and discovery.
Why does drug metabolism research care about the time dimension?
Because drugs and metabolites dynamically 'enter–enrich–clear' in the body; imaging at different time points reconstructs the spatiotemporal distribution, revealing whether they reach the target site or accumulate in non-target tissue in a specific window.
What is the practical benefit of matrix-free for drug metabolism research?
It eliminates spraying, optimization and waiting steps, with samples measured on demand, significantly accelerating evaluation with many time points and dose groups, and avoids matrix-peak interference in the low-mass region.

Get Specifications & Quotation

To obtain detailed specifications, compatible models, or a quotation for the MSI LDPI / DPI full series imaging ion sources, visit the Neo-Source official website, or contact the official team for compatibility advice tailored to your mass spectrometer (Agilent / SCIEX / Thermo and other mainstream MS).

Related Articles

DPI Dual-Photoionization Imaging SourceNeo-Source MSI LDPI Laser Desorption Photoionization imaging ion sourceDrug Distribution: From 'Blood Concentration' to 'Tissue Map'Drug Tissue Distribution Imaging: Breaking an 'Organ' into a 'Tissue Map'Drug Spatial Distribution MSI: From Whole-Tissue Quantification to In-Situ Localization

← Back to MSI Ion Source Knowledge Hub